- In an international study, 1 in 6 people with broken heart syndrome also had cancer.
- Broken heart syndrome, when the heart’s main pumping chamber temporarily enlarges and doesn’t pump well, is known to be associated with emotional stress, but those with cancer were less likely to report an emotional trigger for their heart symptoms.
- Screening patients with broken heart syndrome for cancer and vice versa may help improve their care and increase their lifespan.
Embargoed until 4 a.m. CT / 5 a.m. ET Wednesday, July 17, 2019
(NewMediaWire) - July 17, 2019 - DALLAS - One in six people with broken heart syndrome had cancer and they were less likely to survive for five years after it occurred, according to new international research in Journal of the American Heart Association, the Open Access Journal of the American Heart Association/American Stroke Association.
Broken heart syndrome, also called takotsubo syndrome, occurs when the heart’s main pumping chamber temporarily enlarges and doesn’t pump well. Although the syndrome may feel like a heart attack, with chest pain and shortness of breath, there is no heart muscle damage and no blockage in the coronary arteries feeding the heart. Broken heart syndrome can be triggered by emotional or physical stress, but this international study of patients from 26 centers provides the strongest association yet between the syndrome and cancer.
“Patients with broken heart syndrome might benefit if screened for cancer to improve their overall survival,” said Christian Templin, M.D., Ph.D., senior author of the study and director of Interventional Cardiology of the Andreas Grüntzig Heart Catheterization Laboratories at the University Heart Center Zurich at The University Hospital Zurich in Switzerland.
“Our study also should raise awareness among oncologists and hematologists that broken heart syndrome should be considered in patients undergoing cancer diagnosis or treatment who experience chest pain, shortness of breath, or abnormalities on their electrocardiogram,” Templin said.
Of 1,604 patients with broken heart syndrome in the International Takotsubo Registry, 267 patients or 1 in 6 (average age 69.5 years, 87.6% female) had cancer. The most frequent type of malignancy was breast cancer, followed by tumors affecting the gastrointestinal system, respiratory tract, internal sex organs, skin and other areas.
Compared to those without cancer, researchers found that patients with cancer were:
- Less likely to have experienced an emotional trigger for the syndrome, 18.0% vs. 30.3%.
- More likely to have experienced a physical trigger (such as a medical intervention or physical trauma) prior to the syndrome, 47.9% vs. 34.2%.
- Just as likely to survive for 30 days after the syndrome began, although more likely to die or require intensive heart and respiratory support while in the hospital.
- More likely to die within 5 years after the syndrome began.
The study was too small to analyze whether the worse prognosis in patients with broken heart syndrome and cancer might be due to a specific type or stage of cancer, or the cancer treatments received.
“The mechanism by which malignancy and cancer treatment may promote the development of broken heart syndrome should be explored, and our findings provide an additional reason to investigate the potential cardiotoxic effects of chemotherapy,” Templin said.
Co-authors who contributed equally to the study are Victoria L. Cammann, M.D.; Annahita Sarcon, M.D.; and Jelena R. Ghadri, M.D. Additional co-authors and author disclosures are on the manuscript.
The German Heart Foundation funded the study.
- Available multimedia is on right column of release link - https://newsroom.heart.org/news/broken-heart-syndrome-linked-with-cancer?preview=f9315978f15eb72ffe04617a8ffa62a7
- After July 17, view the manuscript online.
- Complication of broken heart syndrome associated with both short- and long-term risk of death
- Follow AHA/ASA news on Twitter @HeartNews
Statements and conclusions of study authors published in American Heart Association scientific journals are solely those of the study authors and do not necessarily reflect the association’s policy or position. The association makes no representation or guarantee as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations and health insurance providers are available at https://www.heart.org/en/about-us/aha-financial-information.
The American Heart Association is a leading force for a world of longer, healthier lives. With nearly a century of lifesaving work, the Dallas-based association is dedicated to ensuring equitable health for all. We are a trustworthy source empowering people to improve their heart health, brain health and well-being. We collaborate with numerous organizations and millions of volunteers to fund innovative research, advocate for stronger public health policies, and share lifesaving resources and information. Connect with us on heart.org, Facebook, Twitter or by calling 1-800-AHA-USA1.
For Media Inquiries and AHA/ASA Expert Perspective: 214-706-1173
Karen Astle: 214-706-1392; Karen.email@example.com
For Public Inquiries: 1-800-AHA-USA1 (242-8721)